CN104382918B - 一种用于肿瘤局部注射的阿霉素脂质体温敏凝胶 - Google Patents
一种用于肿瘤局部注射的阿霉素脂质体温敏凝胶 Download PDFInfo
- Publication number
- CN104382918B CN104382918B CN201410581506.6A CN201410581506A CN104382918B CN 104382918 B CN104382918 B CN 104382918B CN 201410581506 A CN201410581506 A CN 201410581506A CN 104382918 B CN104382918 B CN 104382918B
- Authority
- CN
- China
- Prior art keywords
- evacet
- thermo
- sensitive gel
- preparation
- adriamycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract description 19
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 69
- 238000002360 preparation method Methods 0.000 claims abstract description 28
- 229940009456 adriamycin Drugs 0.000 claims abstract description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 20
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims abstract description 19
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 18
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 18
- 235000011130 ammonium sulphate Nutrition 0.000 claims abstract description 14
- 239000002904 solvent Substances 0.000 claims abstract description 13
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 7
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims abstract description 5
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- 239000002502 liposome Substances 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 235000019441 ethanol Nutrition 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- KANLKAYGXGSUJC-UHFFFAOYSA-N 2,3-dihydroxypropyl dihydrogen phosphate;sodium Chemical compound [Na].OCC(O)COP(O)(O)=O KANLKAYGXGSUJC-UHFFFAOYSA-N 0.000 claims description 5
- 239000003292 glue Substances 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 4
- 229920005654 Sephadex Polymers 0.000 claims description 3
- 239000012507 Sephadex™ Substances 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000011068 loading method Methods 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 238000009472 formulation Methods 0.000 abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 238000001879 gelation Methods 0.000 abstract description 3
- 229960002901 sodium glycerophosphate Drugs 0.000 abstract description 3
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 abstract description 3
- 230000009885 systemic effect Effects 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 60
- 239000003814 drug Substances 0.000 description 18
- 229920001661 Chitosan Polymers 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- -1 adriamycin lipid Chemical class 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 229940031312 soybean lecithin 500 mg Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410581506.6A CN104382918B (zh) | 2014-10-27 | 2014-10-27 | 一种用于肿瘤局部注射的阿霉素脂质体温敏凝胶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410581506.6A CN104382918B (zh) | 2014-10-27 | 2014-10-27 | 一种用于肿瘤局部注射的阿霉素脂质体温敏凝胶 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104382918A CN104382918A (zh) | 2015-03-04 |
CN104382918B true CN104382918B (zh) | 2017-12-29 |
Family
ID=52600944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410581506.6A Active CN104382918B (zh) | 2014-10-27 | 2014-10-27 | 一种用于肿瘤局部注射的阿霉素脂质体温敏凝胶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104382918B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106822893A (zh) * | 2015-12-07 | 2017-06-13 | 北京大学 | 一种具有微波增敏效果的纳米脂质体及其制备方法和应用 |
CN105520906B (zh) * | 2015-12-24 | 2018-12-04 | 中国药科大学 | 一种载有盐酸阿霉素的温敏自愈水凝胶及其制备方法 |
CN106474050B (zh) * | 2016-11-09 | 2019-10-29 | 中国药科大学 | 一种载有核酸适配体-阿霉素结合物的温敏原位凝胶瘤内注射制剂及其制备方法 |
CN107837229A (zh) * | 2017-11-07 | 2018-03-27 | 中国药科大学 | 一种缓释阿霉素脂质体的温敏水凝胶制剂及制备方法 |
CN110755627A (zh) * | 2019-12-02 | 2020-02-07 | 北京福原科技有限公司 | 4℃呈液态37℃呈固态的温敏性给药材料 |
CN113456579B (zh) * | 2021-07-12 | 2023-04-25 | 南开大学 | 具有双靶点的hdac抑制剂的纳米胶束-水凝胶制剂在治疗急性肾损伤药物中的应用 |
CN113712904B (zh) * | 2021-10-11 | 2023-09-05 | 新疆医科大学第一附属医院 | 一种布地奈德柔性脂质体温敏凝胶及其制备方法 |
CN114767620B (zh) * | 2022-03-16 | 2023-06-27 | 四川省医学科学院·四川省人民医院 | 一种负载藤黄酸的多级响应可注射水凝胶及其用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102258470A (zh) * | 2010-11-01 | 2011-11-30 | 中南大学肝胆肠外科研究中心 | 盐酸阿霉素纳米脂质体制剂的制备 |
CN103834045A (zh) * | 2013-11-07 | 2014-06-04 | 浙江科技学院 | 一种双向可逆温敏凝胶及其制备方法 |
-
2014
- 2014-10-27 CN CN201410581506.6A patent/CN104382918B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102258470A (zh) * | 2010-11-01 | 2011-11-30 | 中南大学肝胆肠外科研究中心 | 盐酸阿霉素纳米脂质体制剂的制备 |
CN103834045A (zh) * | 2013-11-07 | 2014-06-04 | 浙江科技学院 | 一种双向可逆温敏凝胶及其制备方法 |
Non-Patent Citations (3)
Title |
---|
A thermo-and pH-sensitive hydrogel composed of quatemized chitosan/glycerophosphate;Wu J;《Int J Pharm》;20061231;第315卷;第1-11页 * |
Chitosan-based thermosensitive hydrogel containing liposomes for sustained delivery of cytarabine;Mulik R等;《Drug Dev Ind Pharm》;20091231;第35卷(第1期);第49-56页 * |
温敏性壳聚糖凝胶的阿霉素药物体外缓释研究;张维颖等;《中国海洋药物杂志》;20051031;第24卷(第5期);第50-53页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104382918A (zh) | 2015-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104382918B (zh) | 一种用于肿瘤局部注射的阿霉素脂质体温敏凝胶 | |
JP6533626B2 (ja) | 核酸及びキトサンを含む温度感応性ハイドロゲル組成物 | |
CN104434806B (zh) | 一种具有高载药量及主动靶向效应的脂质混合plga纳米粒 | |
CN108653754B (zh) | 一种透明质酸靶向聚多巴胺包覆相变型液态氟碳纳米超声造影剂 | |
CN104940945B (zh) | 一种透明质酸修饰的中空介孔硫化铜复合物及其制备方法与应用 | |
ES2645971T3 (es) | Asociación de poli(N-acriloil glicinamida) con al menos un principio activo | |
CN103230362A (zh) | 氟尼辛葡甲胺注射用原位凝胶及其制备方法 | |
CN104042567A (zh) | 一种蛇葡萄素纳米胶束及其应用 | |
CN109125739A (zh) | 多功能高分子胶束药物递送系统及其制备方法和应用 | |
CN104721131B (zh) | 一种用于肿瘤原位治疗的凝胶制剂及制备方法 | |
CN107837229A (zh) | 一种缓释阿霉素脂质体的温敏水凝胶制剂及制备方法 | |
CN105983097A (zh) | 一种抗肿瘤制剂及其制备方法 | |
CN114288278A (zh) | 一种载药微藻、制备方法及其应用 | |
CN101810577B (zh) | 治疗肿瘤的棉酚静脉注射脂肪乳剂 | |
CN103494780B (zh) | 一种注射用加米霉素组合物冻干粉及制备方法 | |
Depani et al. | Preparation and evaluation of chitosan based thermoreversible gels for intraperitoneal delivery of 5-fluorouracil (5-FU) | |
KR20140133724A (ko) | 저분자 메틸셀룰로오스 기반의 비경구 약물 전달 시스템 | |
CN108186571A (zh) | 可逆交联不对称囊泡在制备治疗急性白血病药物中的应用 | |
CN104984354A (zh) | 聚丙烯酸-磷酸钙复合纳米药物载体及其制备方法和应用 | |
Liu et al. | Metal-organic framework-based injectable in situ gel for multi-responsive insulin delivery | |
CN106214635B (zh) | 一种氟尿嘧啶注射液药物组合物 | |
CN107669637A (zh) | 一种注射用蒿甲醚脂质体及其制备方法和应用 | |
CN104784109B (zh) | 紫杉烷类药物的温敏缓释药物组合物 | |
CN103623413B (zh) | 一种蔗糖酯控释载体材料的制备方法及应用 | |
CN110302389B (zh) | 一种抗血管生成的水凝胶缓释制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240307 Address after: 314000 building 3, Jiake Life Science Park, 3556 linggongtang Road, Daqiao Town, Nanhu District, Jiaxing City, Zhejiang Province Patentee after: Zhejiang Arthur Pharmaceutical Co.,Ltd. Country or region after: China Address before: 310014 science and technology office, Zhejiang University of Technology, No. 18 Chao Wang Road, Xiacheng District, Hangzhou, Zhejiang Patentee before: JIANG University OF TECHNOLOGY Country or region before: China |